HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience.

AbstractPURPOSE:
Radioembolization (RE) is a promising treatment option for biliary tract cancers (BTC). We report here the largest series to date using this treatment modality.
METHODS:
We retrospectively studied data from 64 patients treated outside prospective clinical trial at our institution. We studied baseline characteristics as potential prognostic factors. We studied dose delivered to the tumor as predictive factors of outcomes in patients not receiving concomitant chemotherapy.
RESULTS:
The Progression-Free Survival and Overall Survival (OS) were 7.6 months [95% Confidence Interval (CI): 4.6-10.6] and 16.4 months [95% CI: 7.8-25.0] in the whole cohort. The factors independently associated with OS in multivariable analysis were the primary localization of ICC (HR = 0.27, 95% CI: 0.11-0.68, p = 0.005) and a PS > 0 (HR = 2.21, 95% CI: 1.11-4.38, p = 0.024). During follow-up, 12 patients (19%) underwent surgery following downstaging, with a median OS of 51.9 months. In patients not treated with concomitant chemotherapy (n = 31), OS was significantly higher in patients with a dose delivered to the tumor 260Gy or higher than in patients with a dose delivered to the tumor lower than 260Gy (median 28.2 vs 11.4 months, log-rank p = 0.019).
CONCLUSION:
Our results confirm that RE is a promising treatment modality in BTC. A high proportion of patients could be downstaged to surgery, with promising long-term survival. Dose delivered to the tumor correlated with clinical outcomes when chemotherapy was not used concomitantly.
AuthorsHéloïse Bourien, Xavier Palard, Yan Rolland, Fanny Le Du, Luc Beuzit, Thomas Uguen, Samuel Le Sourd, Marc Pracht, Vincent Manceau, Astrid Lièvre, Karim Boudjema, Etienne Garin, Julien Edeline
JournalEuropean journal of nuclear medicine and molecular imaging (Eur J Nucl Med Mol Imaging) Vol. 46 Issue 3 Pg. 669-676 (03 2019) ISSN: 1619-7089 [Electronic] Germany
PMID30374530 (Publication Type: Journal Article)
Chemical References
  • Yttrium Radioisotopes
  • Yttrium-90
Topics
  • Biliary Tract Neoplasms (therapy)
  • Cohort Studies
  • Embolization, Therapeutic (adverse effects)
  • Female
  • Glass (chemistry)
  • Humans
  • Male
  • Microspheres
  • Retrospective Studies
  • Survival Analysis
  • Yttrium Radioisotopes (adverse effects, chemistry, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: